Please use this identifier to cite or link to this item: https://repositorio.usj.es/handle/123456789/551

Full metadata record
DC FieldValueLanguage
dc.contributor.authorHerrero Cortina, Beatriz-
dc.contributor.authorAlcaraz-Serrano, Victoria-
dc.contributor.authorVilaro, Jordi-
dc.contributor.authorTorres, Antoni-
dc.contributor.authorPolverino, Eva-
dc.date.accessioned2021-04-08T12:56:20Z-
dc.date.available2021-04-08T12:56:20Z-
dc.date.issued2018-
dc.identifier.citationHerrero-Cortina, B., Alcaraz, V., Vilaró, J., Torres, A., Polverino, E., 2018. Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery 31, 281–289.. doi:10.1089/jamp.2017.1443es_ES
dc.identifier.issn1941-2711es_ES
dc.identifier.urihttps://repositorio.usj.es/handle/123456789/551-
dc.description.abstractBackground:The role of hyaluronic acid plus hypertonic saline (HA+HS) as a mucoactive treatment in patientswith bronchiectasis is still unknown. This study evaluated whether HA+HS solution enhances similar sputumquantity with better safety profile than HS alone in patients with bronchiectasis.Methods:In this double-blind randomized crossover trial, three solutions (7% HS; 0.1% HA+7%HS; and 0.9%isotonic saline, IS) were compared in outpatients with bronchiectasis and chronic sputum expectoration. Participantsinhaled each solution across four consecutive sessions. All sessions, except on session 3, also included 30 minutes ofairway clearance technique. A 7-day washout period was applied. Sputum weight was collected during the sessions(primary outcome) as well as during a 24-hour follow-up. The Leicester Cough Questionnaire (LCQ) and lung functionwere measured before/after each treatment arm. Safety was assessed by the monitoring of adverse events (AEs).Results:Twenty-eight patients with bronchiectasis (mean age of 64.0 (17.9) and FEV1% 60.9 (24.6) of predicted) wererecruited. HS and HA+HS promoted similar expectoration during sessions, both being greater than IS [mediandifference HS vs. IS 3.7 g (95% CI 0.5–6.9); HA+HS vs. IS 3.2 g (95%CI 0.5–5.9)]. Sputum expectorated exclusivelyduring the ACT period was similar across all treatment arms [HS vs. IS-0.3 g (95% CI-1.7to0.9);HA+HS vs. IS 0.0 g(95% CI-1.3to1.4);HSvs.HA+HS 0.0 g (95% CI-1.2 to 0.4)]. Sputum collected over the 24-hour follow-up tendedto be lower for HS and HA+HS compared with IS [HS vs. IS-1.7 g (95% CI-4.2to0.0);HA+HS vs. IS-1.1 g (95%CI-3.6 to 0.7)]. No differences in LCQ or lung function were observed. Most severe AEs were reported using HS.Conclusion:HS and HA+HS were more effective on sputum expectoration than IS in patients with bronchi-ectasis, reporting HA+HS better safety profile than HSes_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.relationhis project was sponsored by Praxis Pharmaceuticals and Chiesi Farmaceutici, providing the study drug (hyaluronate acid + hypertonic saline solutions). Funding sources had no involvement in the study concept or design; in the collection, analysis, or interpretation of data; in the writing of the report or in the decision to submit the article for publication.es_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAirway clearance techniqueses_ES
dc.subjectBronchiectasises_ES
dc.subjectHypertonic solutionses_ES
dc.subjectMucoactive treatmentes_ES
dc.subjectSputum expectorationes_ES
dc.titleImpact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.publicationfirstpage281es_ES
dc.identifier.publicationlastpage289es_ES
dc.identifier.doi10.1089/jamp.2017.1443es_ES
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses_ES
Appears in Collections:Artículos de revistas



This item is licensed under a Creative Commons License Creative Commons